Presentations-Debates and Didactics in Hematology/Oncology
prIME Downloadable Slides
prIME Downloadable Slides

Presentations-Debates and Didactics in Hematology/Oncology

2018 Emory Winship Cancer Institute Conference

Not a member of My prIME? Join now for instant access.

View slides created by expert faculty from Winship Cancer Institute and across the nation, presented at the Emory cancer conference, covering controversial topics and standards of care in oncology and hematology. You’ll have the opportunity to see how science supports each point of view.

Downloadable Slides

Downloadable Slides

Release Date

Release Date

Aug 13, 2018

Expiration Date

Aug 13, 2019

Lung Cancer/Head and Neck Cancer/Lymphoma/Leukemia

General principles of immune therapy
Madhav V. Dhodapkar, MBBS

Stage 3 non-small cell lung cancer (NSCLC): Combined modality therapy and immunotherapy
Walter J. Curran, Jr, MD, FACR

Debate 1—What is the best predictive biomarker for immunotherapy in NSCLC?
PD-L1 expression: Conor E. Steuer, MD
Tumor mutation burden: Taofeek Owonikoko, MD, PhD

Targeted therapy for NSCLC: EGFR and ALK
Fadlo R. Khuri, MD, FACP

Treatable molecular targets in NSCLC: BRAF, ROS1, NTRK, and MET
Conor E. Steuer, MD

Present status of immunotherapy for NSCLC
Suresh S. Ramalingam, MD

Debate 2— T4 larynx cancer can be treated with laryngeal conservation
Yes: Jonathan J. Beitler, MD, MBA, FACR, FASTRO
No: Mihir R. Patel, MD

Dose-deintensification in HPV-positive squamous cell carcinoma of the head and neck (SCCHN)
Nabil F. Saba, MD, FACP

What is relevant for front-line treatment of indolent non-Hodgkin lymphoma (iNHL)?
James O. Armitage, MD, FASCO

What is the best approach for iNHL patients with early progression of disease?
Jonathon B. Cohen, MD, MS

Debate 3—What is the best front-line strategy for patients with Hodgkin lymphoma?
ABVD: Christopher R. Flowers, MD
PET-Directed Therapy: Pamela Blair Allen, MD, MSc

Has targeted therapy replaced conventional chemotherapy in chronic lymphocytic leukemia?
Susan M. O’Brien, MD

The role for targeted therapy in relapsed acute lymphoblastic leukemia
Leonard T. Heffner, Jr, MD

Acute myeloid leukemia (AML) moving beyond 7+3 with BEAT AML
William G. Blum, MD

Gastrointestinal Cancers/Multiple Myeloma/ Leukemia/Other Hematologic Topics

Debate 1—Stage IV microsatellite instability (MSI)-high colon cancer: Is there a role for
chemotherapy?
Chemotherapy: Christina Wu, MD
Immune therapy: Bassel El-Rayes, MD

Neuroendocrine tumors: New data, new options
Bassel El-Rayes, MD

Salvage therapy for advanced pancreatic cancer
Christina Wu, MD

Hepatocellular cancer: Immune therapies and novel biologic agents
Walid L. Shaib, MD

Debate 2—Neoadjuvant therapy in resectable colorectal cancer liver metastasis is standard
of care
Yes: Mehmet Akce, MD
No: Shishir K. Maithel, MD, FACS

Prophylaxis and treatment of venous thromboembolism (VTE) in cancer
Christine L. Kempton, MD, MSc

New targets and treatments for relapsed multiple myeloma
Kenneth Anderson, MD

Debate 3—Minimal residual disease testing in multiple myeloma can be used to modify treatment
Yes: Ajay Nooka, MD, MPH, FACP
No: Jonathan L. Kaufman, MD

Induction therapy and transplant for multiple myeloma
Craig C. Hofmeister, MD, MPH

Molecular testing in myeloproliferative neoplasms: A primer
Rebecca B. Klisovic, MD

Debate 4—Targeted therapy vs immune therapy for acute myeloid leukemia (AML)
Targeted therapy: Hagop M. Kantarjian, MD
Immune therapy: William G. Blum, MD

Allo transplant in CR1 for intermediate-risk AML
Amelia A. Langston, MD

Updates in treatment-free remission in chronic myeloid leukemia
Rebecca K. Klisovic

Amyloidosis: Maximal application for best outcomes
Jonathan L. Kaufman, MD

Breast Cancer/Melanoma/Other Hematology Topics

Debate 1—All patients with ductal carcinoma in situ (DCIS) need radiation after lumpectomy
Yes: Mylin A. Torres, MD
No: Cletus A. Arciero, MD, FACS

Optimization of HER2 targeting in early-stage HER2+ breast cancer
Elisavet Paplomata, MD

PARP inhibition for the treatment of breast cancer
Jane Lowe Meisel, MD

Impact of cardiovascular risk modification/obesity on breast cancer outcomes
Keerthi Gogineni, MD, MSHP

Novel targets for cellular therapy in solid tumors
Taofeek Owonikoko, MD, PhD

Debate 2—Adjuvant therapy in melanoma: Immunotherapy vs BRAF/MEK inhibitors
Targeted therapy: Ragini Kudchadkar, MD
Immunotherapy: Melinda L. Yushak, MD, MPH

Indications for complete lymph node dissection for early-stage melanoma
Michael C. Lowe, MD, MA

Systemic therapy for advanced-stage melanoma: What is the present standard of care?
Ragini Kudchadkar, MD

Surveillance of high-risk melanoma: Routine imaging vs clinical follow-up
Melinda L. Yushak, MD, MPH

Tumor treating fields (TTF), antibody-drug conjugates (ADCs), and other advances in brain tumors
Katherine B. Peters, MD, PhD

Comprehensive multidisciplinary care plans for cutaneous T-cell lymphoma
Mary Jo Lechowicz, MD

Debate 3—Salvage therapy for relapsed diffuse large B-cell lymphoma
Auto/Allo: Amelia A. Langston, MD
CAR T: Jonathon B. Cohen, MD, MS

Consultative hematology: Common presentations and workup
Morgan L. McLemore, MD

How phase I trials can improve your patient outcomes
R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA

Genitourinary Cancers

Role of hyperthermic intraperitoneal chemotherapy for ovarian cancer
Charles A. Staley, MD

Immunotherapy in ovarian cancer: Current strategies and future directions
Lesley B. Conrad, MD

Debate 1—Adjuvant tyrosine kinase inhibitor (TKI) should be given for high-risk renal cell
carcinoma (RCC) after nephrectomy
Yes: Viraj Master, MD, PhD, FACS
No: Mehmet Asim Bilen, MD

Immune therapy for bladder cancer
Bradley C. Carthon, MD, PhD

Prostate cancer therapy: What is the present state of the art?
Mehmet Asim Bilen, MD

Immunotherapy for RCC
Michael B. Atkins, MD

After successful completion of this educational activity, participants should be able to:

  • Evaluate the risks and benefits of emerging therapies and novel treatment strategies for patients with solid tumors and hematologic malignancies, as well as the practical utility of these approaches based on recent clinical data
  • Apply best practices regarding the treatment of patients with cancer, including integration of novel therapeutic approaches and individualization of care
  • Appropriately integrate multimodality therapy and multidisciplinary care to improve the management of patients with cancer

This activity is supported by grants from Adaptive Biotechnologies, AstraZeneca, Celgene Corporation, Lilly, and Takeda Oncology.

Enduring Materials From a Certified Activity

This enduring material, derived from a certified live event, contains content that is evidence-based, balanced, and free of commercial bias. While the content was planned and implemented by prIME Oncology for a certified live event, this activity does not offer continuing education credit.

Provider

This activity is jointly provided by prIME Oncology and Winship Cancer Institute of Emory University.

Disclosure Information

Disclosure of Relevant Financial Relationships

prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Anderson has disclosed board membership on the Gilead Scientific Advisory Board. He also disclosed receipt of consulting fees from Bristol-Myers Squibb, Celgene, and Millennium. He further disclosed intellectual property rights and ownership interest as a scientific founder of C4 Therapeutics and OncoPep. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Armitage has disclosed that he has received consulting fees from Ascentage, Conatus (independent data monitoring committee), and Samus Therapeutics. He is also on the board of directors for Tesaro Bio, Inc. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Atkins has disclosed that he has received consulting fees from Array, Bristol-Myers Squibb, Eisai, Exelixis, Genentech, Merck, Novartis, and Pfizer. He has also disclosed independent contracting for Bristol-Myers Squibb and Genentech, and membership on an advisory committee or review panel for Novartis. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Beitler has disclosed that he has received honoraria for a promotional speaker’s bureau from Siemens. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Bilen has disclosed membership on advisory committees or review panels of Exelixis and Sanofi. He has also disclosed receipt of support for institutional research from AstraZeneca, Bayer, Bristol-Myers Squibb, Genentech, Incyte, Peloton, Pfizer, and Seattle Genetics.  He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Cohen has disclosed that he has received consulting fees from AbbVie, Celgene, Genentech, and Janssen. He has also disclosed receipt of research funding from Bristol-Myers Squibb, Novartis, and Takeda. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Curran has disclosed that he received consulting fees from AstraZeneca and Bristol-Myers Squibb. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Dhodapkar has disclosed membership on advisory committees or review panels for Bristol-Myers Squibb and Roche. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr El-Rayes has disclosed that he has received consulting fees from Bayer, Bristol-Myers Squibb, Ipsen, and Roche. He also disclosed honoraria for a promotional speaker’s bureau from Lexicon. He also disclosed independent contracting for Bayer; Boston Biomedical, Inc.; Bristol-Myers Squibb; Johnson & Johnson; Merck; Novartis; and Roche/Genentech. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Flowers has disclosed that he has received consulting fees from AbbVie, Bayer, Denovo Biopharma, Gilead Sciences, Karyopharm, Optum Rx, Pharmacyclics/Janssen, and Spectrum. He has disclosed receipt of research support to his institution from AbbVie, Acerta, Celgene, Gilead Sciences, Genentech/Roche, Janssen Pharmaceuticals, Millennium/Takeda, and TG Therapeutics.  He has also disclosed uncompensated consulting in his role as member on advisory committees or review panels for Celgene and Genentech/Roche. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Gogineni has disclosed membership on an advisory board for Pfizer. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Harvey has disclosed that he has received consulting fees from Genentech and Heron. He has also disclosed independent contracting for AbbVie, Amgen, ArQule, AstraZeneca, Bristol-Myers Squibb, Boston Biomedical, Calithera, Celgene, Cleave, Corvus, Eli Lilly, Five Prime Therapeutics, Genmab, Halozyme, Ignyta, Incyte, Nektar, Novartis, Pfizer, Regeneron, Sanofi, Syndax, and Takeda. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Heffner has disclosed independent contracting for Astex and Pharmacyclics. He has also disclosed membership on an advisory committee or review panel for Pharmacyclics. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Hofmeister has disclosed independent contracting for Bristol-Myers Squibb, Celgene, Janssen, and Takeda. He has also disclosed membership on an advisory committee for Celgene, and funding for speaking and teaching from ASCO and Axis. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Kantarjian has disclosed that he has received honoraria for promotional speaker’s bureaus from AbbVie, Amgen, Ariad, Bristol-Myers Squibb, Immunogen, Orsinex, and Pfizer. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Kaufman has disclosed that he has received consulting fees from AbbVie, Bristol-Myers Squibb, Janssen, and Takeda. He has also disclosed membership on an advisory committee or review panel for Incyte. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Klisovic has disclosed that she is a member of an advisory committee or review panel for Novartis. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Kudchadkar has disclosed that she has received consulting fees from Array and Bristol-Myers Squibb. She has also disclosed receipt of research funding from Merck. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Lechowicz has disclosed participation on a data safety and monitoring board for Soligenix. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Lonial has disclosed that he has received honoraria or consulting fees from Amgen, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Merck, Novartis, and Takeda. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Master has disclosed that he has received fees for participation in advisory boards for ARGOS, Janssen, Merck, and Pfizer. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Nooka has disclosed that he has received consulting fees from Adaptive Technology, Celgene, Janssen, Spectrum, and Takeda. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr O’Brien has disclosed that she has received consulting fees from AbbVie; Alexion; Amgen; Aptose Biosciences, Inc.; Astellas; Celgene; Gilead; GlaxoSmithKline; Janssen Oncology; Pfizer; Pharmacyclics; Sunesis; TG Therapeutics; and Vaniam Group LLC. She has also received research support from Acerta, Gilead, Kite, Pfizer, Pharmacyclics, Regeneron, Sunesis, and TG Therapeutics. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Owonikoko has disclosed that he has received consulting fees from AbbVie, EMD Serono, and GT Therapeutics. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Patel has disclosed that he has been an instructor for Intuitive Surgical. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Peters has disclosed membership on advisory committees or review panels for AbbVie, Agios, Eisai, Monteris, and Novocure. She has also disclosed receipt of research grants from AbbVie, Agios, Eisai, and Novocure. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Ramalingam has disclosed that he has received consulting fees from AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Genentech, Lilly, Merck, and Novartis. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Saba has disclosed that he has received honoraria for a promotional speaker’s bureau from Merck.  He has also disclosed membership on advisory committees or review panels for Bristol-Myers Squibb, Genentech, Kura Oncology, Lilly, Merck, Nanobiotix, and Pfizer. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Shaib has disclosed independent contracting for ArQule Inc.; Boston Biomedical Pharma, Inc.; Covance; Eli Lilly and Company; Hoosier Cancer Research Network, Inc.; and Merck Sharp & Dohme Corporation. He has also disclosed membership on an advisory committee or review panel in an IPSEN Pharmaceutical focus group. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Staley has disclosed that he has received consulting fees from Collegium Pharmaceuticals. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Steuer has disclosed that he has received consulting fees from AbbVie and EMD Serono. He has also disclosed receiving funding for speaking and teaching from Merck.  He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Wu has disclosed independent contracting for Asana; Boston Biomedical, Inc.; Bristol-Myers Squibb, Lycera, and Vaccinex. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

The following faculty members have no relevant financial relationships to disclose. They have agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in their presentation:

Dr Akce

Dr Allen

Dr Arciero

Dr W. Blum

Dr Carthon

Dr Conrad

Dr Kempton

Dr Khuri

Dr Langston

Dr Lowe

Dr Maithel

Dr McLemore

Dr Meisel

Dr Paplomata

Dr Torres

Dr Yushak

The employees of prIME Oncology have disclosed:

  • Briana Betz, PhD (scientific content reviewer/planner) – no relevant financial relationships
  • Heather Tomlinson, ELS (editorial content reviewer) – no relevant financial relationships

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.